Clinical trials: BPH (Benign Prostatic Hyperplasia)
Prostatic Hyperplasia, Kidney Calculi
Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan
A. Synopsis 1. This protocol comes to direct the experiment to be performed on the Aqueduct Automatic Continuous Irrigation system. 2.
- Conditions
- Prostatic Hyperplasia, Kidney Calculi, Bladder Tumors
- Trial name
- NCT02496442
- Testing
- Aqueduct
- Volunteers
- 30 people
- Sponsor
- Flowmed
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Benign Prostate Hyperplasia, Healthy
Safety and Pharmacokinetic Characteristics of DKF-313
This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and tadalafil) in healthy male volunteers.
- Trial name
- NCT02352311
- Testing
- DKF-313, AVODART, CIALIS
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
- Trial name
- NCT07643220
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Benign Prostatic Hyperplasia
Urodynamic Feasibility Study Utilizing the UroLift® System
UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test.
- Trial name
- UDS (NCT04271020)
- Testing
- UroLift
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
BPH
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with…
- Trial name
- NCT00527488
- Testing
- Degarelix
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH) with tamsulosin hydrochloride for at least 6…
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder
- Trial name
- NCT00771394
- Testing
- Tamsulosin hydrochloride, Solifenacin succinate
- Where
- 8 sites in Japan
- Volunteers
- 638 people
- Sponsor
- Astellas Pharma Inc
BPH
Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH
This prospective, multicenter, two-arm, 1:1 randomized controlled trial (RCT) will enroll approximately 250 males at approximately 25 sites located within the United States.
- Trial name
- IMPACT (NCT04987892)
- Testing
- UroLift System, Tamsulosin Hydrochloride
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Benign Prostate Hyperplasia
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).
- Trial name
- NCT02506465
- Testing
- iTIND
- Where
- 13 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in…
- Trial name
- NCT00421421
- Testing
- Dutasteride
- Where
- 25 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00918983
- Testing
- NX-1207
- Where
- 41 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy and safety of Tanzânia association in adults with erectile dysfunction associated with Benign Prostatic Hyperplasia.
- Trial name
- NCT04185441
- Testing
- Tanzânia association, Omnic Ocas
- Where
- Brazil
- Volunteers
- 295 people
- Sponsor
- EMS
Benign Prostatic Hyperplasia (BPH)
China Greenlight Registry Study (Post-market)
The duration of the study is expected to take approximately 3 years, which includes a recruitment period of approximately 12-months and 2 years (24-months) to complete procedure and follow-up visits.
- Trial name
- NCT03736512
- Testing
- GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
- Trial name
- NCT00379067
- Testing
- Tamsulosin OCAS
- Volunteers
- 882 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia (BPH)
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224107
- Testing
- Silodosin
- Where
- 43 sites in United States
- Volunteers
- 461 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia (BPH), Urinary Retention
A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy
To determine the safety and efficacy of the ThermaRx heating device for the application of controlled low level heat to improve symptoms of LUT dysfunction (hesitancy, urgency).
- Conditions
- Benign Prostatic Hyperplasia (BPH), Urinary Retention, Urinary Hesitancy Intermittent
- Trial name
- NCT00700505
- Testing
- FlowPants(R) Garment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ThermaRx, Inc.
Overactive Bladder, Benign Prostate Hyperplasia
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
- Conditions
- Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate, Photoselective Vaporization Prostatectomy
- Trial name
- POST-TURP (NCT01747577)
- Testing
- Solifenacin Succinate
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Astellas Pharma Korea, Inc.